Crystax Pharmaceuticals is the first spanish biotech dedicated to structure-based drug discovery. Located in Barcelona, Crystax was founded in 2002 by recognised scientists Miquel Coll and Juan Aymamí seeking to apply their structural biology knowledge and experience to the drug discovery process.

Our mission is to find the best possible drug in the shortest time and with the highest rate of success.

We aim to achieve this mission through our B2D2™ platform and the commitment of our team.

Our biophysics based drug discovery platform B2D2™, covers the entire process from target cloning to lead optimisation. Through structure determination of target proteins with the fragment hits, we obtain key structural information for the design of new compounds. We also use biophysical characterisation to guide the follow-up of the initial hits. The result is an acceleration of the drug discovery process.